Browse ESR1

Summary
SymbolESR1
Nameestrogen receptor 1
Aliases NR3A1; Era; ESR; ESRA; ESTRR; ER-alpha; estradiol receptor; estrogen nuclear receptor alpha; estrogen recept ......
Chromosomal Location6q24-q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 1: Nucleus Cytoplasm Cell membrane Peripheral membrane protein Cytoplasmic side Note=A minor fraction is associated with the inner membrane.; SUBCELLULAR LOCATION: Isoform 3: Nucleus. Cytoplasm. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Cell membrane; Single-pass type I membrane protein. Note=Associated with the inner membrane via palmitoylation (Probable). At least a subset exists as a transmembrane protein with a N-terminal extracellular domain. ; SUBCELLULAR LOCATION: Nucleus. Golgi apparatus. Cell membrane. Note=Colocalizes with ZDHHC7 and ZDHHC21 in the Golgi apparatus where most probably palmitoylation occurs. Associated with the plasma membrane when palmitoylated.
Domain PF12743 Oestrogen-type nuclear receptor final C-terminal
PF00104 Ligand-binding domain of nuclear hormone receptor
PF02159 Oestrogen receptor
PF00105 Zinc finger
Function

Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full-length receptor. Essential for MTA1-mediated transcriptional regulation of BRCA1 and BCAS3. Isoform 3 can bind to ERE and inhibit isoform 1.

> Gene Ontology
 
Biological Process GO:0001541 ovarian follicle development
GO:0001547 antral ovarian follicle growth
GO:0001655 urogenital system development
GO:0001763 morphogenesis of a branching structure
GO:0002064 epithelial cell development
GO:0002218 activation of innate immune response
GO:0002221 pattern recognition receptor signaling pathway
GO:0002224 toll-like receptor signaling pathway
GO:0002757 immune response-activating signal transduction
GO:0002758 innate immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0003401 axis elongation
GO:0006338 chromatin remodeling
GO:0006352 DNA-templated transcription, initiation
GO:0006367 transcription initiation from RNA polymerase II promoter
GO:0006417 regulation of translation
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0007200 phospholipase C-activating G-protein coupled receptor signaling pathway
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0007548 sex differentiation
GO:0007565 female pregnancy
GO:0008209 androgen metabolic process
GO:0008406 gonad development
GO:0008584 male gonad development
GO:0008585 female gonad development
GO:0009755 hormone-mediated signaling pathway
GO:0010517 regulation of phospholipase activity
GO:0010518 positive regulation of phospholipase activity
GO:0010608 posttranscriptional regulation of gene expression
GO:0010817 regulation of hormone levels
GO:0010863 positive regulation of phospholipase C activity
GO:0016441 posttranscriptional gene silencing
GO:0016458 gene silencing
GO:0017148 negative regulation of translation
GO:0022602 ovulation cycle process
GO:0022612 gland morphogenesis
GO:0030518 intracellular steroid hormone receptor signaling pathway
GO:0030520 intracellular estrogen receptor signaling pathway
GO:0030522 intracellular receptor signaling pathway
GO:0030540 female genitalia development
GO:0030850 prostate gland development
GO:0030879 mammary gland development
GO:0031047 gene silencing by RNA
GO:0031050 dsRNA fragmentation
GO:0031349 positive regulation of defense response
GO:0032355 response to estradiol
GO:0033598 mammary gland epithelial cell proliferation
GO:0034121 regulation of toll-like receptor signaling pathway
GO:0034248 regulation of cellular amide metabolic process
GO:0034249 negative regulation of cellular amide metabolic process
GO:0034250 positive regulation of cellular amide metabolic process
GO:0034502 protein localization to chromosome
GO:0034754 cellular hormone metabolic process
GO:0035194 posttranscriptional gene silencing by RNA
GO:0035195 gene silencing by miRNA
GO:0035196 production of miRNAs involved in gene silencing by miRNA
GO:0035239 tube morphogenesis
GO:0035265 organ growth
GO:0040029 regulation of gene expression, epigenetic
GO:0042445 hormone metabolic process
GO:0042698 ovulation cycle
GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043124 negative regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043331 response to dsRNA
GO:0043401 steroid hormone mediated signaling pathway
GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity
GO:0043627 response to estrogen
GO:0044706 multi-multicellular organism process
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045137 development of primary sexual characteristics
GO:0045727 positive regulation of translation
GO:0046545 development of primary female sexual characteristics
GO:0046546 development of primary male sexual characteristics
GO:0046660 female sex differentiation
GO:0046661 male sex differentiation
GO:0048144 fibroblast proliferation
GO:0048145 regulation of fibroblast proliferation
GO:0048146 positive regulation of fibroblast proliferation
GO:0048511 rhythmic process
GO:0048545 response to steroid hormone
GO:0048608 reproductive structure development
GO:0048732 gland development
GO:0048754 branching morphogenesis of an epithelial tube
GO:0048806 genitalia development
GO:0050673 epithelial cell proliferation
GO:0050727 regulation of inflammatory response
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0055074 calcium ion homeostasis
GO:0060065 uterus development
GO:0060068 vagina development
GO:0060135 maternal process involved in female pregnancy
GO:0060147 regulation of posttranscriptional gene silencing
GO:0060149 negative regulation of posttranscriptional gene silencing
GO:0060191 regulation of lipase activity
GO:0060193 positive regulation of lipase activity
GO:0060442 branching involved in prostate gland morphogenesis
GO:0060443 mammary gland morphogenesis
GO:0060444 branching involved in mammary gland duct morphogenesis
GO:0060512 prostate gland morphogenesis
GO:0060523 prostate epithelial cord elongation
GO:0060525 prostate glandular acinus development
GO:0060526 prostate glandular acinus morphogenesis
GO:0060527 prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis
GO:0060560 developmental growth involved in morphogenesis
GO:0060562 epithelial tube morphogenesis
GO:0060602 branch elongation of an epithelium
GO:0060603 mammary gland duct morphogenesis
GO:0060687 regulation of branching involved in prostate gland morphogenesis
GO:0060688 regulation of morphogenesis of a branching structure
GO:0060736 prostate gland growth
GO:0060737 prostate gland morphogenetic growth
GO:0060740 prostate gland epithelium morphogenesis
GO:0060745 mammary gland branching involved in pregnancy
GO:0060749 mammary gland alveolus development
GO:0060750 epithelial cell proliferation involved in mammary gland duct elongation
GO:0060751 branch elongation involved in mammary gland duct branching
GO:0060964 regulation of gene silencing by miRNA
GO:0060965 negative regulation of gene silencing by miRNA
GO:0060966 regulation of gene silencing by RNA
GO:0060967 negative regulation of gene silencing by RNA
GO:0060968 regulation of gene silencing
GO:0060969 negative regulation of gene silencing
GO:0061138 morphogenesis of a branching epithelium
GO:0061180 mammary gland epithelium development
GO:0061377 mammary gland lobule development
GO:0061458 reproductive system development
GO:0070918 production of small RNA involved in gene silencing by RNA
GO:0070920 regulation of production of small RNA involved in gene silencing by RNA
GO:0071168 protein localization to chromatin
GO:0071359 cellular response to dsRNA
GO:0071383 cellular response to steroid hormone stimulus
GO:0071391 cellular response to estrogen stimulus
GO:0071392 cellular response to estradiol stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:1900274 regulation of phospholipase C activity
GO:1902532 negative regulation of intracellular signal transduction
GO:1903798 regulation of production of miRNAs involved in gene silencing by miRNA
GO:1903799 negative regulation of production of miRNAs involved in gene silencing by miRNA
GO:1905330 regulation of morphogenesis of an epithelium
GO:2000027 regulation of organ morphogenesis
GO:2000241 regulation of reproductive process
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001046 core promoter sequence-specific DNA binding
GO:0001047 core promoter binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001159 core promoter proximal region DNA binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003682 chromatin binding
GO:0003707 steroid hormone receptor activity
GO:0004879 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding
GO:0005496 steroid binding
GO:0008013 beta-catenin binding
GO:0008134 transcription factor binding
GO:0030235 nitric-oxide synthase regulator activity
GO:0030284 estrogen receptor activity
GO:0034056 estrogen response element binding
GO:0038052 RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding
GO:0051117 ATPase binding
GO:0098531 transcription factor activity, direct ligand regulated sequence-specific DNA binding
Cellular Component GO:0000785 chromatin
GO:0000790 nuclear chromatin
GO:0035327 transcriptionally active chromatin
GO:0044454 nuclear chromosome part
> KEGG and Reactome Pathway
 
KEGG hsa04915 Estrogen signaling pathway
hsa04917 Prolactin signaling pathway
hsa04919 Thyroid hormone signaling pathway
hsa04961 Endocrine and other factor-regulated calcium reabsorption
Reactome R-HSA-5688426: Deubiquitination
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-392499: Metabolism of proteins
R-HSA-383280: Nuclear Receptor transcription pathway
R-HSA-1251985: Nuclear signaling by ERBB4
R-HSA-5689896: Ovarian tumor domain proteases
R-HSA-597592: Post-translational protein modification
R-HSA-162582: Signal Transduction
R-HSA-1236394: Signaling by ERBB4
R-HSA-8866910: TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
R-HSA-8864260: Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors
Summary
SymbolESR1
Nameestrogen receptor 1
Aliases NR3A1; Era; ESR; ESRA; ESTRR; ER-alpha; estradiol receptor; estrogen nuclear receptor alpha; estrogen recept ......
Chromosomal Location6q24-q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ESR1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between ESR1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
22420471Basal-Like Breast CarcinomaInhibit immunity (infiltration)In the whole cohort, the presence of intratumoral tumor-infiltrating lymphocytes was significantly correlated with young age, high grade, estrogen receptor negativity, human epidermal growth factor receptor-2 positivity and core basal intrinsic subtype, and was associated with superior breast cancer specific survival.
17237823Breast CarcinomaInhibit immunity (NK cell function)In breast cancer cells, increasing concentrations of estrogen induce increasing levels of the granzyme B inhibitor, SerpinB9/proteinase inhibitor 9 (PI-9) and progressively block cell death induced by NK92 natural killer (NK) cells, but do not block killing by a second NK cell line, NKL cells. RNA interference knockdown of PI-9 abolishes estrogen's ability to block NK92 cell-induced cytotoxicity. Expressing elevated levels of estrogen receptor alpha (ERalpha) increases the induced level of PI-9, and makes tamoxifen (TAM), but not raloxifene or ICI 182,780, a potent inducer of PI-9. At elevated levels of ERalpha, induction of PI-9 by estradiol or TAM blocks killing by both NK92 and NKL cells.
29673712Prostate CarcinomaInhibit immunity (T cell function); immunotherapy targetUpdate on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
29622464breast carcinomaInhibit immunityWe found functionally significant estrogen receptor-regulated long non-coding RNAs (lncRNAs) and gene/lncRNA interaction networks.
29615063breast carcinomaInhibit immunityEstrogen receptor, progesteron receptor, human epidermal growth factor receptor 2, Ki67, PD-L1, PDL-2 and PD-1 status were assessed by immunohistochemistry.
21483002Breast Carcinoma (ERBB-(+))Inhibit immunity (infiltration)The total number of CD8(+) cells was positively correlated with tumor grade (r(s) = 0.20; P < .001) and inversely correlated with patient's age at diagnosis, estrogen receptor-alpha (ER-α), and progesterone receptor (PgR) expression (Mann-Whitney U test, P < .001).
Summary
SymbolESR1
Nameestrogen receptor 1
Aliases NR3A1; Era; ESR; ESRA; ESTRR; ER-alpha; estradiol receptor; estrogen nuclear receptor alpha; estrogen recept ......
Chromosomal Location6q24-q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ESR1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolESR1
Nameestrogen receptor 1
Aliases NR3A1; Era; ESR; ESRA; ESTRR; ER-alpha; estradiol receptor; estrogen nuclear receptor alpha; estrogen recept ......
Chromosomal Location6q24-q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ESR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3350.16
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3580.401
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3220.39
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1750.736
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5980.683
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3470.822
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0320.945
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5070.528
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.5270.552
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0080.988
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4690.498
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3260.0597
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ESR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.811.8-70.577
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.718.2-10.50.576
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolESR1
Nameestrogen receptor 1
Aliases NR3A1; Era; ESR; ESRA; ESTRR; ER-alpha; estradiol receptor; estrogen nuclear receptor alpha; estrogen recept ......
Chromosomal Location6q24-q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ESR1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolESR1
Nameestrogen receptor 1
Aliases NR3A1; Era; ESR; ESRA; ESTRR; ER-alpha; estradiol receptor; estrogen nuclear receptor alpha; estrogen recept ......
Chromosomal Location6q24-q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ESR1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ESR1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolESR1
Nameestrogen receptor 1
Aliases NR3A1; Era; ESR; ESRA; ESTRR; ER-alpha; estradiol receptor; estrogen nuclear receptor alpha; estrogen recept ......
Chromosomal Location6q24-q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ESR1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolESR1
Nameestrogen receptor 1
Aliases NR3A1; Era; ESR; ESRA; ESTRR; ER-alpha; estradiol receptor; estrogen nuclear receptor alpha; estrogen recept ......
Chromosomal Location6q24-q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ESR1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolESR1
Nameestrogen receptor 1
Aliases NR3A1; Era; ESR; ESRA; ESTRR; ER-alpha; estradiol receptor; estrogen nuclear receptor alpha; estrogen recept ......
Chromosomal Location6q24-q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ESR1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolESR1
Nameestrogen receptor 1
Aliases NR3A1; Era; ESR; ESRA; ESTRR; ER-alpha; estradiol receptor; estrogen nuclear receptor alpha; estrogen recept ......
Chromosomal Location6q24-q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ESR1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting ESR1.
ID Name Drug Type Targets #Targets
DB00255DiethylstilbestrolSmall MoleculeAR, ESR1, ESR2, ESRRA, ESRRB, ESRRG, NCOA2, NR1I2, SHBG9
DB00269ChlorotrianiseneSmall MoleculeESR11
DB00286Conjugated estrogensSmall MoleculeESR11
DB00294EtonogestrelSmall MoleculeESR1, PGR2
DB00304DesogestrelSmall MoleculeESR1, PGR2
DB00367LevonorgestrelSmall MoleculeAR, ESR1, PGR, SHBG, SRD5A15
DB00396ProgesteroneSmall MoleculeAR, CYP17A1, ESR1, NR1I2, NR3C1, NR3C2, OPRK1, ORM1, PGR, SHBG10
DB00431LindaneSmall MoleculeESR1, GABRB1, GABRB3, GABRR1, GLRA1, GLRA2, GLRA3, GLRB, NR1I2, PG ......10
DB00481RaloxifeneSmall MoleculeESR1, ESR2, SERPINB9, TFF14
DB00539ToremifeneSmall MoleculeESR1, SHBG2
DB00603Medroxyprogesterone acetateSmall MoleculeESR1, PGR2
DB00624TestosteroneSmall MoleculeAR, ESR1, NR3C23
DB00648MitotaneSmall MoleculeAR, CYP11B1, ESR1, FDX1, PGR5
DB00655EstroneSmall MoleculeAR, CYP19A1, ESR1, ESR2, SHBG5
DB00675TamoxifenSmall MoleculeAR, EBP, ESR1, ESR2, ESRRG, KCNH2, NR1I2, PRKCA, PRKCB, PRKCD, PRK ......16
DB00756HexachloropheneSmall MoleculeESR1, GLUD1, SDHD3
DB00783EstradiolSmall MoleculeBECN1, CHRNA4, ESR1, ESR2, ESRRG, GPER1, HSD17B2, MT-ATP6, NCOA2, ......10
DB00823Ethynodiol diacetateSmall MoleculeESR1, PGR2
DB00841DobutamineSmall MoleculeADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ESR16
DB00882ClomifeneSmall MoleculeESR1, SHBG2
DB00890DienestrolSmall MoleculeESR1, SHBG2
DB00947FulvestrantSmall MoleculeESR11
DB00957NorgestimateSmall MoleculeAR, ESR1, PGR3
DB00977Ethinyl EstradiolSmall MoleculeESR1, NR1I2, SHBG3
DB01065MelatoninSmall MoleculeASMT, CALR, EPX, ESR1, MPO, MTNR1A, MTNR1B, NQO2, RORB9
DB01108TrilostaneSmall MoleculeESR1, ESR2, HSD3B1, HSD3B24
DB01183NaloxoneSmall MoleculeCES1, CREB1, ESR1, OPRD1, OPRK1, OPRM1, TLR47
DB01185FluoxymesteroneSmall MoleculeAR, ESR1, HSD11B2, NR3C1, PRLR5
DB01196EstramustineSmall MoleculeESR1, ESR2, MAP1A, MAP24
DB01357MestranolSmall MoleculeESR11
DB01406DanazolSmall MoleculeAR, CCL2, ESR1, GNRHR, PGR5
DB01428OxybenzoneSmall MoleculeAR, ESR1, ESR2, PGR4
DB01431AllylestrenolSmall MoleculeESR1, PGR2
DB01593ZincSmall MoleculeA1BG, A2M, AGT, AHSG, ALDOA, APCS, APLP1, APLP2, APOA1, APOA2, APO ......119
DB01645GenisteinSmall MoleculeAKT1, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, GPER1, NCOA1, NCOA2, NR1I2 ......13
DB01708PrasteroneSmall MoleculeAR, ESR1, ESR2, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GA ......33
DB01878BenzophenoneSmall MoleculeESR1, ESR22
DB02187EquilinSmall MoleculeESR1, HSD17B12
DB02615Compound 19Small MoleculeESR1, PTPN12
DB02709ResveratrolSmall MoleculeAHR, AKT1, ALOX15, ALOX5, APP, CBR1, CLEC14A, CSNK2A1, ESR1, ITGA5 ......25
DB02715Compound 18Small MoleculeESR11
DB02746Phthalic AcidSmall MoleculeESR1, ESR2, PGR, PPARA, PPARD, PPARG, RXRA, RXRB, RXRG9
DB02757PyrazoleSmall MoleculeADH1C, ESR1, ESR23
DB02901StanoloneSmall MoleculeAR, ESR1, HSD17B1, NR3C24
DB03467NaringeninSmall MoleculeAKR1C1, CYP19A1, CYP1B1, ESR1, ESR2, KANSL3, SHBG7
DB03742Compound 4-DSmall MoleculeESR11
DB038021-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-OlSmall MoleculeESR11
DB04216QuercetinSmall MoleculeACTB, AHR, ATP5A1, ATP5B, ATP5C1, CBR1, CEBPB, CSNK2A1, CSNK2B, CY ......27
DB04468AfimoxifeneSmall MoleculeESR1, ESR2, ESRRA, ESRRG, NR1I2, SHBG, TFF17
DB044712-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-OlSmall MoleculeESR11
DB04573EstriolSmall MoleculeESR1, ESR2, SHBG3
DB04574Estrone sulfateSmall MoleculeESR1, ESR22
DB04575QuinestrolSmall MoleculeESR11
DB04824PhenolphthaleinSmall MoleculeESR1, NR1I2, NR1I3, SHBG4
DB04930PermethrinSmall MoleculeESR1, NR1I2, SCN1A3
DB04938OspemifeneSmall MoleculeESR11
DB05233AP1081Small MoleculeESR11
DB05487CustirsenSmall MoleculeESR1, NFKB1, NFKB23
DB05662NP-50301Small MoleculeESR11
DB05882CHF 4227Small MoleculeESR1, ESR22
DB05966TAS-108Small MoleculeESR1, ESR22
DB06202LasofoxifeneSmall MoleculeCNR2, ESR1, ESR23
DB06249ArzoxifeneSmall MoleculeESR1, ESR22
DB06401BazedoxifeneSmall MoleculeESR1, ESR22
DB06710MethyltestosteroneSmall MoleculeAR, ESR12
DB06732beta-NaphthoflavoneSmall MoleculeAHR, CYP1B1, ESR1, ESRRA, NR2F15
DB0687117-METHYL-17-ALPHA-DIHYDROEQUILENINSmall MoleculeESR1, NCOA22
DB068984-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenolSmall MoleculeESR1, NCOA22
DB06927[5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILESmall MoleculeESR1, ESR2, NCOA13
DB070864-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOLSmall MoleculeESR1, NCOA22
DB070874-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOLSmall MoleculeESR1, NCOA22
DB071954-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOLSmall MoleculeESR1, NCOA22
DB07567(2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OLSmall MoleculeESR11
DB07638(3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OLSmall MoleculeESR1, ESR22
DB07678(9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOLSmall MoleculeESR1, NCOA22
DB07707(9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOLSmall MoleculeESR1, NCOA22
DB077083-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OLSmall MoleculeESR1, NCOA22
DB077123-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OLSmall MoleculeESR1, NCOA22
DB07931HexestrolSmall MoleculeAKR1C1, ESR1, NR1I2, NR1I34
DB07932dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylateSmall MoleculeESR1, NCOA22
DB07933ErteberelSmall MoleculeESR1, ESR22
DB07991N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDESmall MoleculeESR11
DB08020(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OLSmall MoleculeESR1, ESR22
DB080474-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diolSmall MoleculeESR1, NCOA22
DB080484-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOLSmall MoleculeESR1, NCOA22
DB08320DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATESmall MoleculeESR1, NCOA22
DB083982-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridineSmall MoleculeESR1, NCOA22
DB085954-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOLSmall MoleculeESR1, NCOA22
DB08737(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OLSmall MoleculeESR11
DB08773RALOXIFENE CORESmall MoleculeESR1, NCOA22
DB09070TiboloneSmall MoleculeESR11
DB09086EugenolSmall MoleculeAR, ESR1, ESR2, TRPV34
DB09317Synthetic Conjugated Estrogens, ASmall MoleculeESR11
DB09318Synthetic Conjugated Estrogens, BSmall MoleculeESR11
DB09369Polyestradiol phosphateSmall MoleculeESR11
DB09371NorethynodrelSmall MoleculeAR, ESR1, SHBG3
DB09535OctocryleneSmall MoleculeESR1, ESR22
DB11064HomosalateSmall MoleculeAR, ESR1, PGR3
DB11071Phenyl salicylateSmall MoleculeESR11
DB11219EnzacameneSmall MoleculeAR, ESR1, ESR2, PGR4
DB11619GestrinoneSmall MoleculeAR, ESR1, GNRHR, NR3C1, PGR, SHBG6
DB12450Propyl GallateSmall MoleculeESR11
DB138692-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenolSmall MoleculeESR1, ESR22
DB13943Testosterone cypionateSmall MoleculeAR, ESR1, NR3C23
DB13944Testosterone enanthateSmall MoleculeAR, ESR1, NR3C23
DB13946Testosterone undecanoateSmall MoleculeAR, ESR1, NR3C23
DB13951Stanolone acetateSmall MoleculeAR, ESR1, HSD17B1, NR3C24
DB13952Estradiol acetateSmall MoleculeBECN1, CHRNA4, ESR1, ESR2, ESRRG, GPER1, HSD17B2, MT-ATP6, NCOA2, ......10
DB13953Estradiol benzoateSmall MoleculeBECN1, CHRNA4, ESR1, ESR2, ESRRG, GPER1, HSD17B2, MT-ATP6, NCOA2, ......10
DB13954Estradiol cypionateSmall MoleculeBECN1, CHRNA4, ESR1, ESR2, ESRRG, GPER1, HSD17B2, MT-ATP6, NCOA2, ......10
DB13955Estradiol dienanthateSmall MoleculeBECN1, CHRNA4, ESR1, ESR2, ESRRG, GPER1, HSD17B2, MT-ATP6, NCOA2, ......10
DB13956Estradiol valerateSmall MoleculeBECN1, CHRNA4, ESR1, ESR2, ESRRG, GPER1, HSD17B2, MT-ATP6, NCOA2, ......10